
    
      The primary objective of this study is to evaluate the progression-free survival (PFS) in
      previously untreated participants with Stage IIIB/IV non-small cell lung cancer (NSCLC)
      treated with olaratumab plus paclitaxel and carboplatin versus paclitaxel and carboplatin in
      the first-line metastatic setting.
    
  